Bartonella henselae and B. koehlerae bacteremia was documented in two epithelioid hemangioendothelioma patients and B. koehlerae bacteremia in an asymptomatic partner of one of the patients. Considering the biology and clinically variable natural history of epithelioid hemangioendothelioma, these results suggest that chronic Bartonella infection could have a role in the development of this vascular neoplasm. Bartonella spp. are known to induce vasoproliferative tumors in immunocompromised patients and may play a role in the development of epithelioid hemangioendothelioma in immunocompetent patients.
CASE REPORTS
Case 1 was a 37-year-old female who was born in Poland and had lived in Australia for the previous 30 years. Prior to the present illness, she had been generally healthy and routinely participated in a variety of outdoor recreational activities, including advanced skiing, soccer, and competitive cycling. She traveled extensively throughout the Americas, Europe, and Southeast Asia. The patient had experienced numerous insect bites, thought to be fleas, in a San Francisco backpackers' hostel in 1997, which was followed by a brief hospitalization due to cellulitis. Between 1976 and 2011, she had four pet dogs and two pet cats but did not recall seeing fleas on her pets.
Beginning in January 2008, the patient experienced sharp pain in the right upper quadrant of her abdomen; biliary colic was suspected, and the pain resolved within 7 days. Subsequently, abdominal ultrasound and computed tomography (CT) revealed nine distinct lesions, the largest measuring 5.4 cm (segments 5 and 6), 3.1 cm (segment 4b), 2.5 cm (segment 4a), and 2.3 cm (segment 2) in diameter. In February 2008, laparoscopic core and wedge biopsies resulted in a diagnosis of hepatic epithelioid hemangioendothelioma (EHE). The patient underwent a comprehensive liver transplant workup. Lung CT scans performed in 2008 revealed several subcentimeter lung nodules, which were unchanged through 2009. Liver transplantation was advised as the best course of treatment to prevent metastatic disease. The patient elected serial CT scans and was removed from the active liver transplant list. Hashimoto's thyroiditis was diagnosed in December 2008 and treated with iodine supplementation.
Subsequently, three sequential abdominal CT scans identified lesional growth during the next 12 months, and by June of 2009, abdominal CT scans identified 13 lesions and indicated that the two largest lesions were starting to coalesce. The patient elected treatment by multiple irreversible electroporation (IRE). Following the diagnosis of EHE, the patient continued to play soccer and cycle, and her test results remained in the normal range except after each IRE treatment (29 Because of prior detection of Bartonella vinsonii subsp. berkhoffii in an EHE patient (8), a liver biopsy specimen (case 1 only) and blood and serum samples from this EHE patient and an EHE patient from England (case 2) were submitted by the attending physicians to the North Carolina State University Intracellular Pathogens Research Laboratory (IPRL) for attempted isolation or molecular detection of a Bartonella species. A DNeasy tissue kit protocol (Qiagen Inc., Valencia, CA) was used to extract DNA from tissue scrolls cut from the paraffin-embedded liver tissues containing the EHE tumor from patient 1, followed by PCR targeting the 16S-23S intergenic spacer (ITS) region (3, 7, 31) .
Because both patients resided in distant countries, samples were submitted in batches consisting of three blood and serum sample sets obtained at intervals of one to two days. We used a previously described microbiological approach incorporating enrichment cultures of patient blood and serum in Bartonella alphaproteobacteria growth medium (BAPGM), followed by PCR targeting the 16S-23S ITS region (3, 7, 14, 16) . The BAPGM diagnostic platform consists of PCR analysis performed following direct extraction of DNA from blood and serum, enrichment cultures from days 7 and 14, and PCR when colony growth is seen following subculture growth on blood agar plates. Bacterial isolation, PCR amplification, and cloning were performed using previously described methods (3, 7, 14, 16) . Sequences were aligned and compared with GenBank sequences by the use of AlignX7 software (Vector NTI Suite 6.0; InforMax, Inc.) (14) . To assess potential laboratory contamination, an uninoculated BAPGM culture flask was processed simultaneously and in the same manner with each batch of patient blood and serum samples tested. Specifically, while establishing cultures from a batch of samples in a biosafety hood, the top was removed from the BAPGM uninoculated control flask until all patient samples had been processed. Following the standard operating procedures in the IPRL, sample preparation, including BAPGM culture and agar plate subinoculation, DNA extraction, PCR preparation, and PCR amplification and analysis, was performed in separate laboratory rooms to avoid culture as well as DNA contamination. In addition, negative and positive Bartonella PCR controls consisted of DNA extracted from blood free of bacteria and the same DNA spiked with B. henselae genomic DNA at 0.5 genome copies/l, respectively. PCR controls were used for each batch of DNA tested, and negative controls remained negative throughout the study period.
Bartonella koehlerae, B. vinsonii subsp. berkhoffii (genotypes I, II, and III), and B. henselae antibody levels were determined following traditional immunofluorescence antibody assay (IFA) practices (5, 8) with fluorescein-conjugated goat antihuman IgG (Pierce Biotechnology, Rockford, IL). Bartonella vinsonii subsp. berkhoffii genotype I (NCSU CO-1-93) was isolated from a dog with endocarditis. B. koehlerae (NCSU FO-1-09) and B. henselae strain Houston-1 (NCSU FO-93-23) were isolated from naturally infected cats. Bartonella organisms were passed from agar-grown cultures into DH82 cell cultures to obtain IFA antigens. Heavily infected cell cultures were spotted onto 30-well Teflon-coated slides (Cel-Line; Thermo Scientific), dried in air, fixed in acetone, and stored frozen. Serum samples were diluted in phosphate-buffered saline (PBS) solution containing normal goat serum, Tween 20, and powdered nonfat dry milk to block nonspecific antigen binding sites. All available patient sera were screened at dilutions of 1:16 to 1:64. All sera that were reactive at 1:64 were further tested with twofold dilutions out to 1:8, 192 . A cutoff titer of 1:64 was considered to represent seroreactivity.
Initially, B. koehlerae was amplified and sequenced from a stored paraffin-embedded hepatic EHE tissue sample from case 1 obtained in Australia in February 2008. In July 2009, blood and serum were submitted for Bartonella serology, enrichment blood culture, and serial PCR testing as a component of the BAPGM platform ( Table 1) . Testing of the first group of serum and blood samples (July 2009) yielded antibodies to all five test antigens. One of three blood samples was PCR positive, but efforts to sequence the amplicon were unsuccessful. Subsequently, B. vinsonii subsp. berkhoffii genotype I, B. henselae (strain SA2), and B. koehlerae were detected on one, three, and six occasions, respectively. At two time points, PCR results were positive, but efforts to sequence the amplicons were not successful. For 12 months, beginning in September 2009, the patient received azithromycin (500 mg daily) and rifampin (600 mg once daily). During this period, seroreactivity persisted, with Bartonella antibody titers ranging from 1:64 to 1:1,024, and Bartonella DNA sequences were detected in blood or BAPGM enrichment culture samples on several occasions (Table 1). Reviews of liver CT scans spanning a 15-month time period up to September 2010 showed no evidence of tumor progression, and a repeat PET scan (UDP glucose) revealed reduced tracer avidity.
Due to concerns related to horizontal transmission among partners, oral swabs from both individuals were tested. B. koehlerae DNA was amplified and sequenced from one of three swabs obtained from the patient in September 2010. Serology was performed, and six oral swabs and three blood cultures from the patient's cat were concurrently tested. The cat's antibody titers were Ͻ1:16, and no DNA was amplified from the oral swabs, the blood, the serum, or the BAPGM enrichment cultures from days 7 and 14.
Beginning in September 2010, no antibiotics were administered for 6 months, during which time the patient remained asymptomatic. However, when B. henselae DNA was again amplified and sequenced from blood and from a BAPGM enrichment culture in October, doxycycline and rifampin treatment was restarted in April 2011. Retesting in March and May 2011 identified a decrease in seroreactivity to undetectable levels for B. koehlerae and B. vinsonii subsp. berkhoffii genotype I and II antigens. Bartonella DNA was not amplified from the March or May blood, serum, or enrichment blood cultures, and subcultures did not result in bacterial growth.
Case 2 was a 51-year-old female born in England. Retinoblastoma was diagnosed at 30 months of age. As an adult, this individual held an administrative position with minimal historical animal contact. She had traveled to Africa, Asia, Australia, Europe, and North America. When a single blood and serum sample set was tested in the IPRL in April 2010, the patient was not seroreactive to any of the five test antigens. However, B. koehlerae DNA was amplified and sequenced from a BAPGM enrichment blood culture (Table 2 ). When three sample sets were retested in August 2010, the patient was again nonseroreactive, and, with the exception of a positive PCR result following DNA extraction from a blood sample, all other components of the BAPGM platform were PCR negative. Attempts to sequence the amplicon were not successful. When three sample sets were retested in November 2010, antibody reactivity to all five test antigens was found and B. henselae (strain SA2) DNA was amplified and sequenced from one blood sample. In the November sample batch, antibody titers were generally within one dilution of each other; however, as with patient 1, there was a 4-fold or greater (Ͻ16, 64, Ͻ16) variation in B. henselae reciprocal titers corresponding to the three sample collection dates. Partner of patient 1. This 40-year-old male office worker resided in Australia. He had frequent exposure to cats and occasional exposure to dogs but reported infrequent exposure to insects. He had traveled to North and Central America. He was healthy, had not previously sought medical care, and reported no historical or current symptoms. In June and September of 2010, he was seronegative for all five test antigens; however, B. koehlerae DNA was amplified and sequenced from two BAPGM enrichment blood cultures obtained in June and from a September blood sample (Table 3) . B. koehlerae DNA was not amplified from three oral swabs that had been obtained in September, prior to antibiotic treatment. Despite being healthy, and because of repeated documentation of B. koehlerae infection in his girlfriend (case 1), the boyfriend was treated for B. koehlerae bacteremia with azithromycin (500 mg daily) for 14 days beginning 7 September 2010. Following antibiotic treatment for B. koehlerae bacteremia, he was variably seroreactive (titers of 1:64 or 1:128) to three test antigens in October, but seroreactivity to either B. koehlerae or B. vinsonii subsp. berkhoffii genotype II antigens was not detected (Table  3) . Despite documentation of B. koehlerae infection, the patient never seroconverted to that Bartonella antigen. PCR results from tests performed with blood, serum, and enrichment blood cultures obtained in November and December 2010 were negative, and antibodies were no longer detectable in the three December serum samples.
The husband of patient 2 was a 58-year-old company director who reported infrequent animal contact and occasional exposure to mosquitoes and biting flies (Blandford flies). This person had traveled to Africa, Asia, Australia, Europe, and the United States. He reported infrequent illness accompanied by irritability, muscle pain, loss of sensation, and joint pain. During the previous 5 years, he had experienced chronic neck and back pain and was diagnosed with non-insulin-dependent diabetes mellitus. He was seroreactive to Bartonella vinsonii subsp. berkhoffii antigens (all at a titer of 1:64); however, Bartonella DNA was not amplified from blood or BAPGM enrichment blood cultures (Table 3) .
Previously, we reported infection with Bartonella vinsonii subsp. berkhoffii genotype II in a patient with EHE (8) . In this report, we describe sequential documentation of B. henselae, B. koehlerae, and B. vinsonii subsp. berkhoffii genotype I bacteremia in one EHE patient, concurrent B. koehlerae bacteremia in the asymptomatic partner of patient 1, and B. henselae and B. koehlerae bacteremia in a second EHE patient. Epithelioid hemangioendothelioma is a vascular neoplasm of endothelial origin, with malignant potential ranging between benign hemangioma and angiosarcoma. First described by Weiss and Enzinger in 1982 (30) , EHE is characterized by positive immunostaining results for endothelial antigens CD34 and factor VIII. This uncommon cancer usually localizes to hepatic, pulmonary, cutaneous, or bony locations, with the resultant symptoms defined by the site of tumor localization. The natural history of EHE is extremely unpredictable, and there is substantial interpatient variability in disease progression. Intervals of rapid growth are frequently interrupted by long periods of quiescence; however, EHE is generally unresponsive to standard cytotoxic chemotherapy and radiation therapy. Considering the unusual biology and clinically variable natural history of EHE, it seems possible that chronic Bartonella infection could have a causal relationship with the development of this cancer. (11, 12) . Bartonella is the only bacterial genus known to cause endothelial proliferation, presumably by inducing aberrant angiogenic signaling in a manner that is analogous to the angiogenic pathogenesis in malignant tumors (13) . In addition, Bartonellainduced VEGF contributes to noncancerous angioproliferative diseases such as bacillary angiomatosis and peliosis hepatis, most often in immunocompromised patients (10, 12, 20, 27) . On a comparative medical basis, we have previously reported blood culture isolation of B. vinsonii subsp. berkhoffii genotype II from a dog with a hemangiopericytoma and from a dog with bacillary angiomatosis that was concurrently receiving immunosuppressive drug therapy (8, 31) . The association of increased tissue VEGF levels with hemangioendotheliomas also lends credence to the hypothesis that Bartonella infection may be a cause or cofactor in the development of hemangioendotheliomas in some patients (22, 30) . Bartonella henselae causes vasoproliferative lesions in patients with bacillary angiomatosis and bacillary peliosis (26) , and in the context of disease causation, these lesions regress after successful antibiotic treatment (18) . On the basis of in vitro infection of human endothelial cell lines, B. henselae has been shown to induce angiogenesis and endothelial cell proliferation (24) . Bartonella spp. upregulate mitogenic and proinflammatory genes, resulting in cytoskeletal rearrangement and suppression of endothelial cell apoptosis (11, 12) . Infection of human endothelial cells by B. henselae resulted in interleukin-8 (IL-8) production and upregulation of IL-8 receptors such as CXCR2 (19, 25) . IL-8 promotes angiogenesis through enhanced endothelial cell survival and enhanced vascular proliferation (19, 20, 23, 25) . Whether B. koehlerae can induce angiogenesis through the production of hypoxia-inducible factor and vascular endothelial growth factor is unknown. The findings regarding the two EHE patients described in this study, in conjunction with those determined for a previously described EHE patient infected with B. vinsonii subsp. berkhoffii genotype II, suggest that the association between Bartonella infection and EHE should be systematically investigated.
Based upon the serological and sequential PCR test results determined for case 1, it seems likely that the woman was coinfected with three different Bartonella species when the first batch of blood samples was submitted for Bartonella testing. Because different Bartonella species were amplified and sequenced from blood samples from both patients at different time points, it is not possible to confirm whether these patients were coinfected or sequentially infected during the course of study. As B. koehlerae was amplified and sequenced from the EHE liver biopsy sample obtained in February 2008 and from blood and BAPGM enrichment blood cultures tested in March 2010, persistent intravascular infection seems likely. Similarly, B. henselae strain SA2 was amplified and sequenced from blood samples obtained in November 2009 and in June and October 2010. Fewer sample sets were available for sequential testing from patient 2, and only B. koehlerae was detected after enrichment culture. Recently, B. koehlerae bacteremia was documented in eight immunocompetent patients with a spectrum of chronic arthritic, cardiovascular, and neurological symptoms and in a girl with peripheral visual deficits, a sensory neuropathy, and hallucinations (5, 6, 9) . Bartonella vinsonii subsp. berkhoffii and B. henselae bacteremia, as well as coinfection with both organisms, has also been reported in immunocompetent people with substantial arthropod and animal contact (3, 7) . Based upon extensive travel histories, it is likely that both patients were exposed to a spectrum of animal reservoir hosts and transmission-competent insect vectors. Interestingly, patient 1, while traveling in the United States approximately 11 years prior to the diagnosis of EHE, developed severe cellulitis after experiencing numerous flea bites. Patient 2 reported a case of cellulitis, for which antibiotic treatment was prescribed, following bites from Blandford flies. Although the mode(s) and timing of transmission of the Bartonella spp. to these patients remain unknown, it is possible that both individuals were infected by insect bites that occurred years prior to the diagnosis of EHE.
Failure to consistently detect one or more Bartonella species in all three sample sets from a given batch of patient samples could have been related to a number of factors but most likely reflects variability in the level of bacteremia at the time of sample collection. In part, this observation could potentially be associated with a relapsing pattern of bacteremia, as has been reported in studies of cats experimentally infected by blood transfusion and in an experimental rodent model following inoculation of culture-grown bacteria (21, 32) . Trench fever, caused by B. quintana, was historically referred to as Quintan fever due to the remitting febrile episodes that generally occurred at five-day intervals and most likely reflected a relapsing pattern of bacteremia. Clearly, the results from both patients and the boyfriend of patient 1 further illustrate current limitations associated with achieving a serological or molecular diagnosis of bartonellosis. In a few instances, Bartonella sp. DNA could be amplified by PCR; however, the amplicon could not be successfully sequenced, most likely due to a low DNA concentration. It is well recognized that Bartonella spp. are highly fastidious bacteria that require optimized culture conditions for isolation or, alternatively, molecular documentation of infection by PCR amplification and DNA sequencing (1-3). If Bartonella spp. induce a relapsing pattern of bacteremia in people such as occurs in experimentally infected animals, this factor would further complicate microbiological confirmation of bacteremia. Based upon results derived from patient 1, we now routinely test three sample sets obtained every other day over a 1-week collection period.
For patient 1, serological results were congruent with the Bartonella PCR results that were obtained as a result of sequential blood culture attempts; i.e., seroreactivity was demonstrated to each infecting Bartonella sp. eventually found in the patient's blood by PCR. In contrast, patient 2 and the boyfriend of patient 1 were both seronegative at the initial testing time points. Obtaining a batch of three serum samples within a period of several days has allowed us in most instances to document good overall reproducibility of serological results; however, there was an occasional unexplained variation (i.e., a 4-fold or greater variation in antibody titers) in IFA test results within a batch of serum samples. The extent to which this variability might occur in patients infected with Bartonella spp.
is unknown, as, in most instances, antibody testing is rarely repeated at such short testing intervals. Potentially, iatrogenic factors associated with sample collection, shipment, or storage interfered with the IFA testing procedure; alternatively, it is possible that in vivo or in vitro formation of antigen-antibody complexes resulted in lower antibody titers. Patient 2 spontaneously seroconverted to B. vinsonii subsp. berkhoffii, B. henselae, and B. koehlerae antigens during the course of the study, whereas Bartonella antibodies were detected in the boyfriend of patient 1 only following antibiotic treatment. Previously, we reported the lack of a detectable IFA antibody response in patients infected with B. vinsonii subsp. berkhoffii and B. henselae (4, 5) . It is also not unusual in our experience for a seronegative patient to become seroreactive to Bartonella sp. antigens after receiving antibiotic therapy. Whether this observation reflects the movement of the bacteria from a sequestered intracellular location to an extracellular site where antigenic recognition of the bacteria by the host is enhanced or whether antigenic recognition is enhanced by antibiotic-induced injury or bacterial death is not known.
Repeated documentation of B. koehlerae in the boyfriend of patient 1 potentially supports the hypothesis of a common source of exposure (fleas or the pet cat, despite the negative test results) or the possibility of horizontal transfer of this bacterium by an as-yet-undetermined route(s). As the pet cat was seronegative and PCR negative (according to blood, serum, and oral swab test results), it was considered an unlikely source of infection. In contrast, B. koehlerae DNA was amplified and successfully sequenced from an oral swab sample provided by patient 1. Despite amplification of B. koehlerae DNA from the blood, oral swabs simultaneously obtained from the boyfriend of patient 1 on three consecutive days were PCR negative. Detection of B. koehlerae DNA in an oral swab does not confirm the presence of viable bacteria or, alternatively, if the bacteria are viable, whether oral transmission can actually occur. Bartonella DNA has previously been found in salivary samples from cats, dogs, and a bacteremic human patient with periodontal disease (1, 15) . In addition, family clusters involving two or more patients infected with the same Bartonella spp. and strains have been recently reported (4, 5) . Clearly, additional studies are required to better define modes of Bartonella transmission among vectors, animals, and people.
Based upon sequential serological and enrichment PCR testing results from patient 1 spanning a 22-month time period, therapeutic elimination of Bartonella infection in some EHE patients may be difficult to achieve. Similarly, B. henselae (strain SA2) was repeatedly amplified from blood, serum, or enrichment blood cultures from a veterinarian, despite extended courses of antibiotics (28) . In conclusion, our findings do not confirm that B. koehlerae, B. henselae, and B. vinsonii subsp. berkhoffii are a cause of EHE. However, if the proposed association of Bartonella spp. with EHE were to be confirmed, it is plausible that eradicating the bacterial infection or interrupting Bartonella-induced angiogenic and proliferative cell signals could slow tumor progression and improve patient outcomes. As a novel WWTR1-CAMTA1 gene fusion in 17 EHE tumors was recently identified, the role of Bartonella and the bacteriophages contained in B. henselae and B. vinsonii subsp. berkhoffii as potential causes of recurrent chromosomal translocation involving CAMTA1 on 1p36.23 and WWTR1 on 3q25.1 should be investigated (17) .
